Table 1 Demographic and clinical characteristics of the patients (modified intention-to-treat population).

No.

188

65

68

55

Age, median (IQR), y

40.00 [29.00, 52.25]

41.00 [31.00, 54.00]

35.50 [26.50, 49.25]

43.00 [31.50, 51.50]

0.272

>60 y (%)

21 (11.2)

9 (13.8)

7 (10.3)

5 (9.1)

0.706

Sex (%)

0.068

female

74 (39.4)

20 (30.8)

34 (50.0)

20 (36.4)

male

114 (60.6)

45 (69.2)

34 (50.0)

35 (63.6)

Symptom type of patients (%)

Symptomatic

119 (63.3)

44 (67.7)

42 (61.8)

33 (60.0)

0.648

Had symptoms at enrolment

52 (27.7)

19 (29.2)

16 (23.5)

17 (30.9)

0.646

Fever

5 (2.7)

3 (4.6)

0 (0.0)

2 (3.6)

0.231

Cough

48 (25.5)

17 (26.2)

16 (23.5)

15 (27.3)

0.912

Asymptomatic

69 (36.7)

21 (32.3)

26 (38.2)

22 (40.0)

Days from first nucleic acid test to randomization (%)

0.755

≤ 3 days

101 (53.7)

33 (50.8)

39 (57.4)

29 (52.7)

4–5 days

87 (46.3)

32 (49.2)

29 (42.6)

26 (47.3)

Vaccine (%)

0.149

Not vaccinated

32 (17.0)

8 (12.3)

14 (20.6)

10 (18.2)

Vaccinated, 1–2 doses

67(35.7)

18 (27.7)

28 (41.2)

21 (38.2)

Vaccinated, 3 doses

89 (47.3)

39 (60.0)

26 (38.2)

24 (43.6)

Have Chinese traditional medicine (%)

134 (71.3%)

50 (76.9)

44 (64.7)

40 (72.7)

0.301

Patients at high risk of developing severe COVID-19 (%)*

98 (52.4)

35 (53.8)

36 (53.7)

27 (49.1)

0.868

With underlying chronic disease

36 (19.1)

13 (20.0)

14 (20.6)

9 (16.4)

Age > 60 y

21 (11.2)

9 (13.8)

7 (10.3)

5 (9.1)

BMI > 25 kg/m²

47 (25.1)

16 (24.6)

17 (25.4)

14 (25.5)

Cigarette smoking

50 (26.6)

18 (27.7)

18 (26.5)

14 (25.5)